BioAdaptives (OTC: BDPT) announced the upcoming commercial launch of XcellaraHeart(TM), a cardiovascular wellness supplement that combines the company’s Xcellara(TM) stem/progenitor cell mobilization formula with Tanshinone IIA, a bioactive compound derived from Danshen root. The company said the Xcellara(TM) base is supported by a randomized, double-blind, placebo-controlled clinical trial that demonstrated an average 268.8% increase in circulating primitive stem/progenitor-type cells after four weeks, while Tanshinone IIA has been studied for its effects on the SDF-1α/CXCR4 signaling pathway associated with cellular trafficking and cardiovascular repair biology.
XcellaraHeart(TM) is scheduled to be available for order beginning Aug. 1, 2026, with initial deliveries expected in early August. BioAdaptives said the product is designed around a two-part cardiovascular wellness strategy combining stem/progenitor cell mobilization with cardiovascular signaling support, and that a scientific evidence dossier detailing the formulation is available on the company’s product website.
To view the full press release, visit https://ibn.fm/G14S7
About BioAdaptives(R) Inc.
BioAdaptives(R) Inc. is the developer of the Xcellara(TM) line of stem cell mobilization and tissue-homing supplements. The Company’s flagship Xcellara(TM) base formula is the only dietary supplement with a human randomized, double-blind, placebo-controlled clinical trial demonstrating a 268.8% increase in circulating hematopoietic stem and progenitor cells at four weeks with zero adverse effects on more than twenty blood parameters. The Xcellara product line includes seven targeted formulas combining the clinically proven mobilization base with tissue-specific signaling ingredients for cardiac, joint, neural, dermal, longevity, and stress-resilience applications. For more information, visit products.xcellara.com.
The complete scientific evidence dossier for the XcellaraHeart(TM) formulation will be available at products.xcellara.com/science. The dossier separates what has been demonstrated in BioAdaptives’ human clinical research on the Xcellara(TM) base from published research on Tanshinone IIA and from the Company’s product-development rationale for combining the two.
For more information, please visit our website at www.bioadaptives.com.
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]
InvestorWire is powered by IBN